{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T14:19:18Z","timestamp":1789913958923,"version":"4.0.1"},"reference-count":32,"publisher":"SAGE Publications","issue":"11","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2005,11]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Inappropriate medication use in patients with heart failure (HF) presents challenges in providing optimal, evidence-based care.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>OBJECTIVE<\/jats:title>\n                    <jats:p>To evaluate the incremental differences of concurrent and persistent use of angiotensin-converting enzyme (ACE) inhibitors, \u03b2-blockers, loop diuretics, and digoxin on the one-year, all-cause risk of hospitalization and total healthcare costs associated with treatment of HF in patients enrolled in a managed care organization within the US.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>A retrospective database analysis was conducted spanning from January 1, 1997, to December 31, 1999. Multivariate regression methods were used to examine the association between treatment regimens and hospitalizations or costs after controlling for patient demographics and risk factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Of the 1903 patients meeting inclusion criteria, 32.3% (n = 615) received none of the 4 HF agents studied and were associated with a 2.5 times greater risk (p \u2264 0.001) of hospitalization and 43.6% higher (p \u2264 0.001) total costs compared with all other patients with HF. Comparatively, 13.9% (n = 264) utilized the HF medications investigated for at least 6 months. Of those with persistent use of \u22653 agents, approximate decreases in hospitalizations were noted of 80% (p \u2264 0.001) and total costs of 70% (p \u2264 0.001) relative to patients receiving no HF therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>A substantial portion of patients with HF may be receiving suboptimal pharmacotherapeutic care in real-world practice settings, potentially incurring large increases in hospitalizations and total costs. Quality improvement initiatives should seek to identify and manage those not being treated according to guideline recommendations.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1g124","type":"journal-article","created":{"date-parts":[[2005,10,11]],"date-time":"2005-10-11T23:23:42Z","timestamp":1129073022000},"page":"1785-1791","source":"Crossref","is-referenced-by-count":10,"title":["Incremental Effects of Concurrent Pharmacotherapeutic Regimens for Heart Failure on Hospitalizations and Costs"],"prefix":"10.1177","volume":"39","author":[{"given":"Grant H","family":"Skrepnek","sequence":"first","affiliation":[{"name":"Grant H Skrepnek PhD BSPharm, Assistant Professor, College of Pharmacy, University of Arizona, Tucson, AZ; Investigator, Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Abarca","sequence":"additional","affiliation":[{"name":"Jacob Abarca PharmD MS, Assistant Research Scientist, Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C","family":"Malone","sequence":"additional","affiliation":[{"name":"Daniel C Malone PhD BSPharm, Associate Professor, College of Pharmacy, University of Arizona; Investigator, Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Edward P Armstrong PharmD BCPS, Professor, College of Pharmacy, University of Arizona; Investigator, Center for Health Outcomes and PharmacoEconomic Research, College of Pharmacy, University of Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farshad M","family":"Shirazi","sequence":"additional","affiliation":[{"name":"Farshad M Shirazi MD PhD, Assistant Professor, College of Medicine, University of Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L","family":"Woosley","sequence":"additional","affiliation":[{"name":"Raymond L Woosley MD PhD, Professor, College of Medicine, University of Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2005,11,1]]},"reference":[{"key":"bibr1-aph.1G124","volume-title":"Heart disease: a textbook of cardiovascular medicine","author":"Braunwald E","year":"1997","edition":"5"},{"key":"bibr2-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9149(85)90789-1"},{"key":"bibr3-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(93)90455-A"},{"key":"bibr4-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(99)00358-6"},{"key":"bibr5-aph.1G124","volume-title":"Heart disease and stroke statistics\u20142004 update","year":"2003"},{"key":"bibr6-aph.1G124","volume-title":"The heart, arteries, and veins","author":"Hurst W","year":"1998","edition":"9"},{"key":"bibr7-aph.1G124","volume-title":"2001 Medicare and Medicaid statistical supplement","author":"Health care financing review","year":"2003"},{"key":"bibr8-aph.1G124","first-page":"219","volume-title":"Pharmacotherapy: a pathophysiologic approach","author":"Parker RB","year":"2005","edition":"6"},{"key":"bibr9-aph.1G124","unstructured":"9. Hunt SA, Baker DW, Chin MH, Cinquergrani MP, Feldman AM, Francis GS, ACC\/AHA Guidelines for the evaluation and management of chronic heart failure in the adult. Dallas: American Heart Association, 2001: 1\u201356."},{"key":"bibr10-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-9164(99)91340-4"},{"key":"bibr11-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000014771.38666.22"},{"key":"bibr12-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301"},{"key":"bibr13-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199605233342101"},{"key":"bibr14-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199702203360801"},{"key":"bibr15-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001"},{"key":"bibr16-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)01187-2"},{"key":"bibr17-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)02213-3"},{"key":"bibr18-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-8703(99)70005-0"},{"key":"bibr19-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2004.01.041"},{"key":"bibr20-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/61.19.2043"},{"key":"bibr21-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000138934.28340.ED"},{"key":"bibr22-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.19.2517"},{"key":"bibr23-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1592\/phco.24.4.351.33175"},{"key":"bibr24-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199508000-00004"},{"key":"bibr25-aph.1G124","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2005.11.3.240"},{"key":"bibr26-aph.1G124","first-page":"83","volume-title":"Principles of pharmacoeconomics","author":"Skrepnek GH","year":"2005","edition":"3"},{"key":"bibr27-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(04)90069-0"},{"key":"bibr28-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(95)00381-9"},{"key":"bibr29-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.160.2.197"},{"key":"bibr30-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1002\/sim.4780100110"},{"key":"bibr31-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(97)80122-1"},{"key":"bibr32-aph.1G124","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.16.1749"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1G124","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1G124","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1G124","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:09:20Z","timestamp":1777374560000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1G124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["10.1345\/aph.1G124"],"URL":"https:\/\/doi.org\/10.1345\/aph.1g124","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11]]}}}